IL296484B2 - Pharmaceutical formulations of HIF hydroxylase inhibitor - Google Patents

Pharmaceutical formulations of HIF hydroxylase inhibitor

Info

Publication number
IL296484B2
IL296484B2 IL296484A IL29648422A IL296484B2 IL 296484 B2 IL296484 B2 IL 296484B2 IL 296484 A IL296484 A IL 296484A IL 29648422 A IL29648422 A IL 29648422A IL 296484 B2 IL296484 B2 IL 296484B2
Authority
IL
Israel
Prior art keywords
dye
capsule
red
iron oxide
yellow
Prior art date
Application number
IL296484A
Other languages
English (en)
Hebrew (he)
Other versions
IL296484B1 (en
IL296484A (en
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL296484(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of IL296484A publication Critical patent/IL296484A/en
Publication of IL296484B1 publication Critical patent/IL296484B1/en
Publication of IL296484B2 publication Critical patent/IL296484B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL296484A 2013-06-06 2014-06-05 Pharmaceutical formulations of HIF hydroxylase inhibitor IL296484B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361831909P 2013-06-06 2013-06-06
PCT/US2014/041021 WO2014197660A1 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor

Publications (3)

Publication Number Publication Date
IL296484A IL296484A (en) 2022-11-01
IL296484B1 IL296484B1 (en) 2024-11-01
IL296484B2 true IL296484B2 (en) 2025-03-01

Family

ID=51063834

Family Applications (3)

Application Number Title Priority Date Filing Date
IL296484A IL296484B2 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of HIF hydroxylase inhibitor
IL298998A IL298998B2 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor
IL242759A IL242759B2 (en) 2013-06-06 2015-11-24 Pharmaceutical formulations of hif hydroxylase inhibitor

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL298998A IL298998B2 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor
IL242759A IL242759B2 (en) 2013-06-06 2015-11-24 Pharmaceutical formulations of hif hydroxylase inhibitor

Country Status (24)

Country Link
US (3) US20160120859A1 (enExample)
EP (2) EP3708154A1 (enExample)
JP (4) JP6604941B2 (enExample)
KR (3) KR20220164069A (enExample)
CN (5) CN110448537A (enExample)
AU (1) AU2014274890B2 (enExample)
CA (1) CA2914049C (enExample)
CY (1) CY1122951T1 (enExample)
DK (1) DK3003284T3 (enExample)
ES (1) ES2786924T3 (enExample)
HR (1) HRP20200615T1 (enExample)
HU (1) HUE049623T2 (enExample)
IL (3) IL296484B2 (enExample)
LT (1) LT3003284T (enExample)
ME (1) ME03777B (enExample)
MX (3) MX2015016536A (enExample)
PL (1) PL3003284T3 (enExample)
PT (1) PT3003284T (enExample)
RS (1) RS60464B1 (enExample)
SG (1) SG11201509764RA (enExample)
SI (1) SI3003284T1 (enExample)
SM (1) SMT202000190T1 (enExample)
WO (1) WO2014197660A1 (enExample)
ZA (1) ZA201508712B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004031114D1 (de) 2003-06-06 2011-03-03 Fibrogen Inc Stickstoffhaltige heteroarylverbindungen und deren verwendungen zur erhoehung des gehaltes von endogenem erythropoietin
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
BR112015001101A2 (pt) 2012-07-16 2017-06-27 Fibrogen Inc formas cristalinas de um inibidor de prolil hidroxilase
CN103435546B (zh) 2012-07-16 2016-08-10 菲布罗根有限公司 制备异喹啉化合物的方法
KR20220164069A (ko) 2013-06-06 2022-12-12 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
MX374909B (es) 2015-04-01 2025-03-06 Akebia Therapeutics Inc El uso del inhibidor de propil hidrolasa del factor inducible de hipoxia (hif) para el tratamiento o prevención de la anemia.
WO2019042485A1 (en) 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
JP7144510B2 (ja) * 2017-09-04 2022-09-29 サンド・アクチエンゲゼルシヤフト 経口投与可能なｈｉｆプロリルヒドロキシラーゼ阻害剤の共結晶
CN110664814A (zh) * 2019-10-24 2020-01-10 上海长海医院 Fg-4592在制备治疗炎性肠病药物中的用途
CN110934833B (zh) * 2019-12-17 2022-08-19 河北长天药业有限公司 一种复方氨酚那敏颗粒
JP2023518392A (ja) * 2020-03-17 2023-05-01 ザイダス ライフサイエンシズ リミティド Ｈｉｆプロリルヒドロキシラーゼ阻害剤を含む製剤組成物
WO2022192097A1 (en) * 2021-03-06 2022-09-15 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
CN116832005A (zh) * 2022-03-23 2023-10-03 石药集团中奇制药技术（石家庄）有限公司 一种罗沙司他胶囊
CN114796280B (zh) * 2022-06-15 2024-06-25 河北长天药业有限公司 一种复方氨酚那敏颗粒及其制备工艺
EP4321155A1 (en) 2022-08-08 2024-02-14 Sanovel Ilac Sanayi Ve Ticaret A.S. An oral pharmaceutical composition comprising roxadustat
WO2025111214A1 (en) 2023-11-22 2025-05-30 Fibrogen, Inc. [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds)
CN118436652A (zh) * 2024-04-18 2024-08-06 南方医科大学顺德医院(佛山市顺德区第一人民医院) 一种罗沙司他药物制剂及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090099203A1 (en) * 2007-10-12 2009-04-16 Astrazeneca Ab Composition 064
US20100172984A1 (en) * 2006-06-06 2010-07-08 Bijay Kumar Padhi tablet dosage form comprising cetirizine and pseudoephedrine
US20120149712A1 (en) * 2001-12-06 2012-06-14 Fibrogen, Inc. Methods for improving kidney function
WO2012097331A1 (en) * 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2003053997A2 (en) 2001-12-06 2003-07-03 Fibrogen, Inc. Methods of increasing endogenous erythropoietin (epo)
DE10209692A1 (de) 2002-03-06 2003-09-18 Merck Patent Gmbh Isochinolinderivate
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
RS58025B1 (sr) 2002-12-16 2019-02-28 Kissei Pharmaceutical Co Ltd Lekovi u čvrstom stanju za oralnu upotrebu
JP4805234B2 (ja) * 2002-12-16 2011-11-02 キッセイ薬品工業株式会社 経口固形医薬
DE602004031114D1 (de) 2003-06-06 2011-03-03 Fibrogen Inc Stickstoffhaltige heteroarylverbindungen und deren verwendungen zur erhoehung des gehaltes von endogenem erythropoietin
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2005011696A1 (en) 2003-08-01 2005-02-10 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
EP1726306B1 (en) * 2004-03-16 2013-10-30 Asahi Kasei Pharma Corporation Fasudil-containing preparation and method of improving stability thereof
ATE513833T1 (de) 2005-03-02 2011-07-15 Fibrogen Inc Thienopyridinverbindungen und verfahren zu ihrer verwendung
US20060276477A1 (en) 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
JP5410751B2 (ja) 2005-06-15 2014-02-05 ファイブローゲン、インコーポレーテッド がん治療のための化合物および方法
UA97349C2 (uk) * 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
WO2007052592A1 (ja) 2005-10-31 2007-05-10 Kowa Co., Ltd. 光安定性に優れた医薬製剤
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
CN101374815B (zh) 2006-01-27 2013-07-17 菲布罗根有限公司 使低氧诱导因子（hif）稳定的氰基异喹啉化合物
RS51330B (sr) * 2006-02-09 2011-02-28 Teva Pharmaceutical Industries Ltd. Stabilne farmaceutske formulacije montelukast natrijuma
KR20080097446A (ko) 2006-02-16 2008-11-05 피브로겐, 인크. 뇌졸중의 치료를 위한 화합물과 방법
KR101084635B1 (ko) 2006-04-04 2011-11-18 피브로겐, 인크. Ｈｉｆ 조절제로서 피롤로- 및 티아졸로-피리딘 화합물
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
JP5683058B2 (ja) * 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
CN101917996A (zh) 2007-11-02 2010-12-15 法布罗根股份有限公司 降低血压的方法
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
US20110039885A1 (en) 2007-12-06 2011-02-17 Fibrogen, Inc. Methods for increasing endothelial progenitor cells
WO2009075826A1 (en) 2007-12-07 2009-06-18 Fibrogen, Inc. Methods for increasing white blood cells
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
CN102264740B (zh) 2008-08-20 2014-10-15 菲布罗根有限公司 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
WO2010024908A1 (en) 2008-08-26 2010-03-04 Fibrogen, Inc. Methods for treatment of multiple sclerosis
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
US20100144737A1 (en) 2008-12-08 2010-06-10 Fibrogen, Inc. Methods for inhibiting t helper cell differentiation
JP5591128B2 (ja) 2009-01-29 2014-09-17 大日本住友製薬株式会社 内核を有する口腔内崩壊錠
JP2010248106A (ja) * 2009-04-14 2010-11-04 Dainippon Sumitomo Pharma Co Ltd フィルムコーティング錠
JP2012176899A (ja) 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
CN103429240A (zh) 2011-01-13 2013-12-04 菲布罗根有限公司 增加平均红细胞体积的方法
US8921389B2 (en) 2011-02-02 2014-12-30 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
JP6099644B2 (ja) 2011-07-22 2017-03-22 ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
WO2013070908A1 (en) 2011-11-09 2013-05-16 Fibrogen, Inc. Therapeutic method
JP6129217B2 (ja) 2012-03-09 2017-05-17 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼインヒビターとしての４−ヒドロキシ−イソキノリン化合物
CN103435546B (zh) 2012-07-16 2016-08-10 菲布罗根有限公司 制备异喹啉化合物的方法
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
BR112015001101A2 (pt) 2012-07-16 2017-06-27 Fibrogen Inc formas cristalinas de um inibidor de prolil hidroxilase
RU2666144C2 (ru) 2013-01-24 2018-09-06 Фиброген, Инк. Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты
KR20220164069A (ko) 2013-06-06 2022-12-12 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120149712A1 (en) * 2001-12-06 2012-06-14 Fibrogen, Inc. Methods for improving kidney function
US20100172984A1 (en) * 2006-06-06 2010-07-08 Bijay Kumar Padhi tablet dosage form comprising cetirizine and pseudoephedrine
US20090099203A1 (en) * 2007-10-12 2009-04-16 Astrazeneca Ab Composition 064
WO2012097331A1 (en) * 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content

Also Published As

Publication number Publication date
HRP20200615T1 (hr) 2020-07-10
SI3003284T1 (sl) 2020-08-31
IL242759A (enExample) 2015-12-31
IL298998A (en) 2023-02-01
DK3003284T3 (da) 2020-03-30
CN111728950A (zh) 2020-10-02
KR20210104173A (ko) 2021-08-24
IL296484B1 (en) 2024-11-01
RU2015151056A3 (enExample) 2018-05-03
ES2786924T3 (es) 2020-10-14
JP2021100971A (ja) 2021-07-08
CN111728951A (zh) 2020-10-02
KR102291860B1 (ko) 2021-08-20
KR20220164069A (ko) 2022-12-12
PT3003284T (pt) 2020-08-10
RU2015151056A (ru) 2017-07-14
BR112015029693A8 (pt) 2019-12-24
MX2022011225A (es) 2022-10-07
CN110448537A (zh) 2019-11-15
CA2914049C (en) 2021-10-12
CN105377242A (zh) 2016-03-02
EP3708154A1 (en) 2020-09-16
CN111728952A (zh) 2020-10-02
HUE049623T2 (hu) 2020-09-28
BR112015029693A2 (pt) 2017-07-25
JP2016523846A (ja) 2016-08-12
IL242759B2 (en) 2023-05-01
NZ754196A (en) 2021-06-25
IL242759B1 (en) 2023-01-01
SMT202000190T1 (it) 2020-05-08
ME03777B (me) 2021-04-20
RS60464B1 (sr) 2020-07-31
IL298998B1 (en) 2024-03-01
US20160120859A1 (en) 2016-05-05
IL296484A (en) 2022-11-01
US20220054474A1 (en) 2022-02-24
IL298998B2 (en) 2024-07-01
CY1122951T1 (el) 2021-10-29
RU2681304C2 (ru) 2019-03-06
CA2914049A1 (en) 2014-12-11
PL3003284T3 (pl) 2020-08-10
NZ714554A (en) 2021-06-25
ZA201508712B (en) 2020-07-29
HK1222550A1 (en) 2017-07-07
WO2014197660A1 (en) 2014-12-11
MX2020003096A (es) 2020-08-17
EP3003284A1 (en) 2016-04-13
EP3003284B1 (en) 2020-02-12
JP2023068197A (ja) 2023-05-16
US10765672B2 (en) 2020-09-08
JP6604941B2 (ja) 2019-11-13
JP6861758B2 (ja) 2021-04-21
JP2019137703A (ja) 2019-08-22
KR20160018514A (ko) 2016-02-17
AU2014274890A1 (en) 2015-12-17
MX2015016536A (es) 2016-08-11
US20190008846A1 (en) 2019-01-10
SG11201509764RA (en) 2015-12-30
AU2014274890B2 (en) 2019-10-03
LT3003284T (lt) 2020-04-27

Similar Documents

Publication Publication Date Title
IL296484B2 (en) Pharmaceutical formulations of HIF hydroxylase inhibitor
IL279036B1 (en) Pharmaceutical combination, composition, and combination formulation comprising glucokinase activator and sglt-2 inhibitor and preparation methods and uses thereof
KR102173092B1 (ko) 루테인 장용성 고체분산체를 유효성분으로 함유하는 위산보호용 조성물 및 이를 포함하는 경구용 제제
NZ754196B2 (en) Pharmaceutical formulations of a HIF hydroxylase inhibitor
HK1222550B (en) Pharmaceutical formulations of a hif hydroxylase inhibitor
HK40032448A (en) Pharmaceutical formulations of a hif hydroxylase inhibitor
NZ714554B2 (en) Pharmaceutical formulations of a hif hydroxylase inhibitor
BR112015029693B1 (pt) Comprimido e cápsula compreendendo ácido [(4-hidróxi-1-metil-7-fenóxi-isoquinolina-3-carbonil)-amino]-acético
KR20140112747A (ko) 리파아제 저해제의 용출율이 증진되고 부작용이 감소된 약학적 제제 및 그의 제조방법